DEPRESCRIBING PADA LANSIA DENGAN POLIFARMASI: DAMPAK TERHADAP OUTCOME KLINIS, KUALITAS HIDUP, DAN KEAMANAN OBAT – SUATU TINJAUAN LITERATUR
DOI:
https://doi.org/10.70248/jophs.v2i4.3318Abstract
Background: Polypharmacy in older adults is associated with higher risks of adverse drug events (ADE), potentially inappropriate medications (PIM), hospitalisation, and mortality. Deprescribing has emerged as a structured clinical approach to optimise medication use, although its clinical outcomes remain inconsistent. Objective: This review aimed to summarise the current evidence regarding the effectiveness and safety of deprescribing interventions in older adults with polypharmacy. Methods: A structured literature review was conducted using PubMed/MEDLINE, Scopus, Google Scholar, and grey literature sources published between 2010–2025. Search terms included “older adults”, “polypharmacy”, “deprescribing”, and “medication review”. Eligible studies included clinical trials, quasi-experimental studies, and systematic reviews reporting deprescribing outcomes in older adults. Data were analysed narratively due to heterogeneity of methods and outcomes. Results: Most deprescribing interventions were based on explicit criteria (Beers, STOPP/START) or pharmacist-led medication reviews. Strong evidence supports deprescribing to reduce the number of medications and PIM in various clinical settings. However, findings regarding ADE, hospitalisations, and mortality remain inconsistent. The variability is partly explained by short follow-up duration, clinical heterogeneity, and differences in deprescribing models. Despite this, deprescribing appears safe, clinically acceptable, and well received by older adults and healthcare providers. Conclusion: Deprescribing improves medication optimisation and safety in older adults, although conclusive evidence on major clinical outcomes is still limited. Structured and multidisciplinary deprescribing approaches should be encouraged, particularly in primary care. Local studies are needed to evaluate long-term clinical effects and implementation feasibility in Indonesia.
References
S. Chua, A. Todd, E. Reeve, S. M. Smith, J. Fox, Z. Elsisi et al., “Deprescribing interventions in older adults: An overview of systematic reviews,” PLoS One, vol. 19, no. 6, e0305215, 2024, doi: 10.1371/journal.pone.0305215.
D. Zhou, Z. Chen and F. Tian, “Deprescribing interventions for older patients: A systematic review and meta-analysis,” J. Am. Med. Dir. Assoc., 2024, doi: 10.1016/j.jamda.2024.105305.
A. M. Linsky et al., “Deprescribing in community-dwelling older adults: A systematic review and meta-analysis,” JAMA Netw. Open, 2025 (online ahead of print).
N. Veronese et al., “Efficacy of deprescribing on health outcomes: An umbrella review,” Ageing Res. Rev., 2024, doi: 10.1016/j.arr.2024.101XXXX.
W. Thompson and E. G. McDonald, “Polypharmacy and deprescribing in older adults,” Annu. Rev. Med., vol. 75, pp. 1–16, 2024, doi: 10.1146/annurev-med-070822-101947.
M. Liacos, A. T. Page and C. Etherton-Beer, “Deprescribing in older people,” Aust. Prescr., vol. 43, pp. 114–120, 2020, doi: 10.18773/austprescr.2020.033.
H. E. Bloomfield et al., “Deprescribing for community-dwelling older adults,” J. Gen. Intern. Med., 2020, doi: 10.1007/s11606-020-05869-5.
H. W. Quek et al., “The effect of deprescribing interventions on mortality and hospitalisation in older patients: a systematic review and meta-analysis,” Br. J. Clin. Pharmacol., 2024, doi: 10.1111/bcp.16200.
“Deprescribing in older adults with polypharmacy: Clinical review,” BMJ, vol. 385, 2023, doi: 10.1136/bmj-2023-074892.
“Polypharmacy and deprescribing in older people,” The Pharmaceutical Journal, Aug. 12, 2025.
N. Masnoon, S. Shakib, L. Kalisch-Ellett and G. E. Caughey, “What is polypharmacy: A systematic review of definitions,” BMC Geriatr., vol. 17, p. 230, 2017, doi: 10.1186/s12877-017-0621-2.
R. L. Bushardt, E. B. Massey, T. W. Simpson, J. C. Ariail and K. N. Simpson, “Polypharmacy: misleading, but manageable,” Clin. Interv. Aging, vol. 3, no. 2, pp. 383–389, 2008, doi: 10.2147/CIA.S2468.
T. K. Gandhi et al., “Adverse drug events in ambulatory care,” N. Engl. J. Med., vol. 348, no. 16, pp. 1556–1564, 2003, doi: 10.1056/NEJMsa020703.
J. R. Nebeker, P. Barach and M. H. Samore, “Clarifying adverse drug events: A clinician’s guide to terminology, documentation, and reporting,” Ann. Intern. Med., vol. 140, no. 10, pp. 795–801, 2004, doi: 10.7326/0003-4819-140-10-200405180-00009.
N. Masnoon et al., “Prevalence and factors associated with polypharmacy: A systematic review and meta-analysis,” BMC Geriatr., vol. 22, p. 601, 2022, doi: 10.1186/s12877-022-03279-x.
N. N. Ngcobo, Z. Majola and M. Rossouw, “Polypharmacy and deprescribing among geriatric patients: A contemporary review,” Explor. Res. Clin. Soc. Pharm., vol. 100, 2025 (online ahead of print).
J. W. Wastesson, S. Morin, K. Tan and K. Johnell, “An update on the clinical consequences of polypharmacy in older adults: A narrative review,” Expert Rev. Clin. Pharmacol., vol. 11, no. 8, pp. 743–752, 2018, doi: 10.1080/14740338.2018.1546841 .
H. Wu, S. Wastesson, S. Bell and J. Johnell, “Deprescribing in the older patient: A narrative review of challenges and opportunities,” Ther. Adv. Drug Saf., vol. 12, p. 20420986211013918, 2021, doi: 10.1177/20420986211013918.
A. M. Linsky and A. Trivedi, “Deprescribing to reduce medication harms in older adults,” in Making Healthcare Safer IV, Rockville, MD: AHRQ, 2024.
C. H. Kua, V. S. L. Mak and S. W. Lee, “Health outcomes of deprescribing interventions among older residents in nursing homes: A systematic review and meta-analysis,” J. Am. Med. Dir. Assoc., vol. 20, no. 3, pp. 362–372.e11, 2019, doi: 10.1016/j.jamda.2018.10.026.
K. Ibrahim et al., “A systematic review of the evidence for deprescribing interventions among older people living with frailty,” BMC Geriatr., vol. 21, p. 258, 2021, doi: 10.1186/s12877-021-02208-8.
E. E. Vasilevskis et al., “Deprescribing medications among older adults from end of hospital stay to home: The Shed-MEDS randomized clinical trial,” JAMA Intern. Med., vol. 183, no. 1, pp. 40–50, 2023, doi: 10.1001/jamainternmed.2022.5263.
C. Pétein, A. Spinewine and S. Henrard, “Deprescribing benzodiazepine receptor agonists in older adults: A systematic review of clinical practice guidelines and implementation barriers,” Drugs Aging, vol. 41, 2024 (online ahead of print), doi: 10.1007/s40266-024-01085-0.
I. Bužančić et al., “Deprescribing potential of commonly used medications among community-dwelling older adults: Insights from a pharmacist’s geriatric assessment,” Sci. Rep., vol. 14, Article 56780, 2024, doi: 10.1038/s41598-024-56780-1.
J. R. Gonçalves, C. Lemos and N. Ribeiro, “Pharmacist-mediated deprescribing in long-term care facilities: A systematic review,” Pharmacy, vol. 13, no. 1, p. 3, 2025, doi: 10.3390/pharmacy13010003.
C. Campabadal Prats et al., “Effectiveness of a structured pharmaceutical review of pharmacotherapeutic plans to reduce drug-related problems in nursing homes: Study protocol of a pragmatic quasi-experimental trial,” Front. Pharmacol., vol. 16, Article 1522650, 2025, doi: 10.3389/fphar.2025.1522650.
T. D. Hughes, E. Sottung, J. Nowak and K. A. Sanders, “Pharmacist-led deprescribing of opioids and benzodiazepines in older adults: Examining implementation and perceptions,” Pharmacy, vol. 12, no. 4, p. 119, 2024, doi: 10.3390/pharmacy12040119.
E. G. McDonald et al., “Electronic decision support for deprescribing in older adults in long-term care: A stepped-wedge cluster randomized trial,” JAMA Netw. Open, vol. 8, no. 7, e2321456, 2025, doi: 10.1001/jamanetworkopen.2025.21456.
